SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

INNV RSS Feed
Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, cash4, Peter Lynch, pharmacyman
Search This Board: 
Last Post: 6/26/2017 7:36:35 PM - Followers: 123 - Board type: Free - Posts Today: 0

  


http://www.innovuspharma.com

https://twitter.com/innovuspharma


http://shop.innovuspharma.com/
* shareholders, please consider purchasing product(s)


***ALERT***

Awaiting Official Announcement of FDA Approval for FlutiCare



 
FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.
 

 


The CEO has already signed an agreement for the manufacturing of FlutiCare

 
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.
 



 

Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)
 

 
 

Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.


Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.


Bassam Damaj, Ph.D.
President and Chief Executive Officer:


Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
 



Who are the major players at Innovus Pharma?




 

Share Structure:


Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 

 
 
Products:
https://www.ooyess.bargains/

http://www.innovuspharma.com/products_OTC_mh.php#top



Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call
http://finance.yahoo.com/news/innovus-pharma-ceo-provides-shareholder-101000536.html

https://www.youtube.com/watch?v=FT9MP0OiMqU

https://www.youtube.com/watch?v=w-FKfRaSj0Y

https://www.youtube.com/watch?v=f7YnqjVLVg0

https://www.youtube.com/watch?v=mqM_dY5Wz3s




Corporate Presentation November 2016 (8-K  11/1/2016)
http://client.irwebkit.com/innovuspharma/filings?qm_page=38298


Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)
http://finance.yahoo.com/news/upcoming-pdufa-anda-approval-dates-140000806.html


Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products
http://finance.yahoo.com/news/innovus-pharma-innv-targeting-3-150320014.html




Major 2016 Accomplishments:



 

 


Where can INNV products be seen?





 


Existing Product Lines @ Innovus Pharma:

http://shop.innovuspharma.com/


Newest Product:

http://www.prostagorx.com/

WHAT IS PROSTAGORX™?

PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


_________________________________________________________________________________________________________________________________________________________________________
















Are you looking to boost your brain health?r
               http://www.recalmax.com/


http://www.urivarx.com/





http://www.myandroferti.com/

https://www.myvesele.com/

https://www.ooyess.bargains/

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

INNV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Current Report Filing (8-k) 06/20/2017 06:11:03 AM
INNV News: Current Report Filing (8-k) 06/19/2017 06:05:31 AM
INNV News: Current Report Filing (8-k) 05/22/2017 06:05:29 AM
INNV News: Current Report Filing (8-k) 05/16/2017 06:12:08 AM
INNV News: Quarterly Report (10-q) 05/15/2017 06:11:33 AM
PostSubject
#9455  Sticky Note Heavily shorted almost 3 Mil shares looking to cover. cash4 05/23/17 10:41:56 AM
#9167  Sticky Note 10-Q Our Products BooDog 05/15/17 07:56:30 AM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#10399   no its a trade through a full service TrueTrades 06/26/17 07:36:35 PM
#10398   I know etrade will let you do it kkpennies 06/26/17 07:09:19 PM
#10396   once again, Pre market or After Hours trading TRUMPFORPRES 06/26/17 03:07:38 PM
#10393   Thanks Shawn, Itz weird. mike007 06/26/17 01:32:19 PM
#10392   They must know something. Could be a nasty ShawnP123 06/26/17 01:24:18 PM
#10391   Question, how do you pm trading this. I mike007 06/26/17 01:19:16 PM
#10390   Of course he wants his circle of friends TRUMPFORPRES 06/26/17 01:08:55 PM
#10389   He also brought all his buddies from Apricus. ShawnP123 06/26/17 11:28:13 AM
#10388   How can you dilute 100M shares and walkaway TRUMPFORPRES 06/26/17 11:17:20 AM
#10387   wow thats awful TrueTrades 06/26/17 10:59:39 AM
#10386   PL- healthywealth is critical of anyone who posts ShawnP123 06/26/17 10:49:11 AM
#10385   no they are not empty words, I am Peter Lynch 06/26/17 10:45:10 AM
#10384   Empty words, empty words , empty words healthywelth 06/26/17 10:21:26 AM
#10383   dilution dilution dilution - that's the name of Peter Lynch 06/26/17 09:51:40 AM
#10382   Nobody likes dilution, but if you take over jtaylor68 06/23/17 02:46:22 PM
#10381   ill alert the media TrueTrades 06/23/17 02:17:19 PM
#10380   lol and now its not. MM games... 2 jbdiver 06/23/17 02:11:11 PM
#10379   0.13 mcklewis88 06/23/17 02:09:08 PM
#10378   We are up! mcklewis88 06/23/17 02:06:51 PM
#10377   He did the RS under NexMed and 3 ShawnP123 06/23/17 01:57:33 PM
#10375   Shawn, you haven't even read my posting. That's jtaylor68 06/23/17 12:43:35 PM
#10374   innv 3 months ending march, 31 2017 TrueTrades 06/23/17 12:08:01 PM
#10372   TF- You are correct about the relationship between ShawnP123 06/23/17 12:02:44 PM
#10370   another day of MM games and illiquidity with jbdiver 06/23/17 09:35:19 AM
#10366   So your mission against Damaj was tied to jtaylor68 06/23/17 07:43:32 AM
#10365   So you are sure it wasn't a sweetheart jtaylor68 06/23/17 07:40:43 AM
#10362   taylor: he purchased Bio-Quant from APRI while he twistedfreak 06/23/17 06:26:47 AM
#10361   Jtaylor, as far as Damaj's tenure at APRI, twistedfreak 06/23/17 06:04:39 AM
#10360   I think you're right kkpennies 06/22/17 11:33:21 PM
#10359   I got a day job kkpennies 06/22/17 11:29:05 PM
#10358   INNV is heading in the right direction and BooDog 06/22/17 07:54:45 PM
#10357   You asked. Whats your point? Not so reticent. jtaylor68 06/22/17 07:45:20 PM
#10356   save your breath TrueTrades 06/22/17 07:35:16 PM
#10355   I certainly haven't studied his vita to exhaustion, jtaylor68 06/22/17 07:30:55 PM
#10354   I got 9 holes golf coming with Bassam Honeycomb777 06/22/17 07:28:23 PM
#10353   you bet TrueTrades 06/22/17 07:23:27 PM
#10350   Tweet Tweet / Post Post to HC, Political, Honeycomb777 06/22/17 07:13:47 PM
#10349   shit boo there is no reason to plunk TrueTrades 06/22/17 06:59:27 PM
#10348   When Q4 is in black and white I BooDog 06/22/17 06:46:51 PM
#10347   do you know about damaje yourself? TrueTrades 06/22/17 06:45:04 PM
#10346   Thanks. I was particularly interested in your take jtaylor68 06/22/17 06:35:45 PM
#10345   $2.5m in revenues is high range this q TrueTrades 06/22/17 06:26:00 PM
#10344   TrueTrades, as a sharp critic of Damaj, what jtaylor68 06/22/17 06:23:13 PM
#10343   Why would you have to change your entire jtaylor68 06/22/17 06:04:05 PM
#10342   yeah might make it to .12 in a TrueTrades 06/22/17 06:02:06 PM
#10341   Chart is stacking up nicely, mcklewis88 06/22/17 05:01:12 PM
#10340   To be more clear, I don't care kkpennies 06/22/17 04:55:53 PM
#10339   Well if you believe that the government has twistedfreak 06/22/17 04:54:42 PM
#10338   Free promo would be better. You somehow believe kkpennies 06/22/17 04:43:26 PM
#10337   Yeah, KK, I'm sure that paid infomercial PR twistedfreak 06/22/17 04:39:46 PM
PostSubject